We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Intraperitoneal Chemotherapy for Gastric Cancer: Promising Survival Signals but Very Low‑Certainty Evidence

MedXY Editorial Team•Dec 16, 2025•Gastroenterology
Gastric CancerHIPECintraperitoneal chemotherapyperitoneal metastasis

Highlights

– A 2025 Cochrane review including nine randomized trials (829 participants) evaluated intraperitoneal chemotherapy (IPC) for both prophylaxis and treatment of peritoneal disease in gastric cancer.

– IPC (mostly hyperthermic intraperitoneal chemotherapy, HIPEC) showed an apparent survival benefit (prophylactic HR 0.66; therapeutic HR 0.52), but certainty is very low because of risk of bias, indirectness, and imprecision.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Clinical Outcomes and Prognostic Factors in Lung Metastases Following Gastrectomy for Gastric CancerThis review summarizes the clinical characteristics, disease course, and survival outcomes of lung metastases after gastrectomy in gastric cancer patients, highlighting prognostic factors and the role of pulmonary metastasectomy.Sep 7, 2026Unveiling the Molecular Evolution from Primary Gastric Cancer to Peritoneal Metastases: Implications for Targeted Surgical OncologyThis study elucidates transcriptomic differences between primary gastric cancers and peritoneal metastases, revealing distinct tumor microenvironments and molecular pathways, highlighting potential targets for improved diagnosis and therapySep 5, 2026Genomic Profiling of Primary Gastric Tumors Predicts Recurrence Patterns and Survival OutcomesGenomic alterations in primary gastric tumors, including KRAS and PIK3CA mutations, correlate with recurrence risk and metastatic patterns, informing personalized postoperative surveillance and treatment strategies.Aug 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression
SOX9 is a pivotal regulator of SPEM cell plasticity driving gastric metaplasia and carcinogenesis. Therapeutically targeting SOX9 may prevent the progression of pre-cancerous lesions to gastric cancer by blocking metaplastic evolution.
Jul 16, 2026
Laparoscopic HIPEC as Consolidation Therapy in Advanced Epithelial Ovarian Cancer: Feasibility and Impact on Quality of LifeLaparoscopic HIPEC following upfront treatment in advanced epithelial ovarian cancer is feasible, safe, and preserves patient quality of life, offering a promising consolidation approach.Aug 18, 2026
Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: Phase 3 TrialA phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.Jun 10, 2026